One of the Vital Drivers for Migraine Drugs Market Is the Developing Awareness About Types of Headache and Its Treatment Alternatives

The Global Migraine Drug Market is projected to reach USD 4.90 billion by 2021 owing to expanding requirement for new treatment choices

Posted: Thursday, February 01, 2018 at 2:45 AM CST

Hyderabad, Telangana -- (SBWire) -- 02/01/2018 --According to a new market research report "Migraine Drugs Market by Treatment (Preventive And Absorptive) By Therapeutic Class (Triptants, Ergots And Others) - Global Forecast to 2022", published by Market Data Forecast™, the market is expected to reach USD 5.2 Billion by 2022 from USD 4.08 Billion in 2017, at a CAGR of 5.9%. Factors driving the growth of this market include developing rate of headache and the increase of high neglected needs in this market, a few organizations have begun putting resources into the R&D of headache drugs.

Browse Market Data Tables and Figures spread through 186 Pages and in-depth TOC on "Migraine Drugs Market"
Early buyers will receive 10% customization on this report

By treatment, the Migraine Market is classified into preventive and adsorptive. The preventive Drugs segment is expected to lead the global Migraine Market in 2017. Factors driving the growth of this segment include the wide use of preventive treatment measure for migraine pain as it can proceed to other brain ailments.

Customized Report:

By therapeutic class, the market is segmented into triptans, ergots and others,. The triptans are serotonin receptor agonist drug class. Ergot class of drugs are no longer prescribed as they have potential side effects and can cause severe damage.

The expanding requirement for new treatment choices has encouraged to the improvement of new devices, for example, ant migraine devices and headbands in the market. Coaly Transcutaneous Electrical Nerve Stimulation devices is a FDA confirmed devices for headache treatment. This device stimulates the trigeminal nerve with electric streams and gives relief from headache.

Request Sample:

Based on region, the Migraine Drugs Market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to dominate the Migraine Market in 2017 followed by APAC. This is attributed to factors such patents and R&D on various combination of drugs to prevent or completely cure this diseases, and technological advancements of Migraine products in the region as compared to other regions.

Key players in the Migraine Drugs Market include Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories. The other prominent vendors the market include AbbottAeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, Bayer, CoLucid, Eli Lilly, IntelGenx, Ethypharm, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Dr. Reddy's Laboratories, OptiNose, Pozen,Eisai, Raptor, RedHill, SUDA, Teva, , Aegis Therapeutics, Merck, TG Therapeutics, NValeant, Winston Pharmaceuticals, Allergan, and Zogenix.

The scope of the report provides:
The evaluation of the current market for your product or services and the future implications of the market
Addresses the opportunities by better understanding the market through size estimates and growth rate analysis to forecast the market for the future
Extensive segmentation to understand the dynamics of market at a very granular level by splitting down the market to the smallest segment
Addresses the key market dynamics involving the drivers, restraints and challenges with an aim of providing insights for gaining market share
The factors responsible for the shaping of the industry as it is as a result of competitive environment is analyzed through Porter's Five Forces
The effects of political, economic, social, technological, legal and environmental factors on the industry is analyzed through PESTLE analysis to better understand the aspects of strategic management required to comply with the exogenous and endogenous factors
Strategic evaluation of the key players to gain insights of their performance allowing access to their product portfolio, financial performance and the strengths of their business strategic developments
Comparative study of the firms across the industry measuring their performances based on market share and recent activities in order to achieve competitive intelligence
Equip you with the information providing with the investment opportunities in the industry
Looking for more? If you are in need of a specific research study, we have an expertise in undertaking a customized study and will aid to meet your research requirement to the fullest.

Browse Related Reports
Nuclear Medicine Radiopharmaceuticals Market by Diagnostics (SPECT, PET), by Therapeutics (Beta Emitters, Alpha Emitters, Brachytherapy), by Application (cardiology, lymphoma, thyroid, neurology oncology) and by Region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market by Medication (Stimulants-Amphetamines, Non-Stimulants-Bupropion), Psychotherapy (Behavior Therapy, Cognitive Behavioral Therapy), and Education or Training (Parent Management Training, Family Therapy) - Global Market Analysis, Size, Geographic Regional Analysis, Competitive Strategies Analysis and Forecasts (2016 to 2021)

Sleep Aids Market by Sleep Disorder (Insomnia, Sleep Apnea, Restless legs syndrome, Narcolepsy and Sleep walking), by Product (Mattresses & Pillows, Sleep Laboratories, Medication and Sleep apnea devices), by Medication (Prescription-based Drugs, OTC drugs and Herbal Drugs), and by Region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

Contact Info:
Name: Mr. Abhishek Shukla
Organization: MarketDataForecast™
Address: 2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
Phone: +1-888-702-9626

Global Migraine Drug Market